Breaking News: MediPharm Labs Expands Legal Team Adding Cannabis Expertise and Announces Participation at Upcoming Conferences

MediPharm Labs Corp. (TSX-V: LABS) (OTCQB: MLCPF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce it has expanded its legal team with the recent appointment of Daniel Everall, B. Comm, JD, as Director of Legal. 

The Company also announced its participation at upcoming investor conferences in April 2019:

  • BMO Capital Markets 2019 Cannabis Conference, April 4, 2019 – Toronto
  • GMP Securities Cannabis Conference, April 16, 2019 – Toronto

MediPharm Labs participates in investor presentations and conferences throughout the year. Interested parties can find a schedule of these and other conferences in upcoming events at

Company Expands Legal Team Adding Cannabis Expertise

Daniel Everall joins MediPharm Labs after 7 years at Aird & Berlis LLP, where he summered and articled before becoming an associate in the firm’s Capital Markets Group, a founding member of its Cannabis Group and a Director of its Startups Team. There he focused on securities law, M&A, cannabis regulatory compliance and general corporate and commercial matters. He also frequently acted as counsel to cannabis and non-cannabis startups seeking to scale-up and commercialize their products. Daniel played an integral role in advising MediPharm Labs Inc. on their reverse take-over of POCML 4 Inc. (and TSX-V listing) and $22.3 million private placement. He holds a Juris Doctor from University of Toronto’s Faculty of Law and a Bachelor of Commerce (with distinction) from the University of Alberta.

About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the ACMPR without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to produce purified, pharmaceutical-grade cannabis oil and concentrates for advanced derivative products. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream extraction methodologies and purpose-built facilities to deliver pure, safe and precisely-dosed cannabis products to patients and consumers. MediPharm Labs’ private label program is a high margin business for the Company, whereby it opportunistically procures dry cannabis flower and trim from its numerous product supply partners, to produce proprietary cannabis oil concentrate products for resale globally on a private label basis.

Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

[popuppress id=”204304″]

  1. Trent Miller 4 years ago

    I will be at the GMP Securities Cannabis Conference, hopefully the team can help educate me on new extraction methods such as distillation. Smoking dabs as a method of consumption has been around for at least a decade, but the advent of more advanced extraction methods have led to a flood of cannabis concentrates that have boosted dabbing’s popularity.

    • Rebecca Ungarino 4 years ago

      cannabis distillate is one of my favorites, burn at a lower temp and enjoy the flavor. Lightens up the psychoactive effects which is what i’m aiming for

  2. Luke Noles 4 years ago

    having cannabis expertise is invaluable for companies as the cannabis market has so much potential

Leave a Comment